|
Clinical Question: Does nateglinide effective in the
treatment of nonalcoholic steatohepatitis (NASH) patients with type 2
diabetes?
Bottom Line: Nateglinide is useful in the treatment of NASH
in patients with type 2 diabetes.
Reference: Nateglinide is useful for nonalcoholic
steatohepatitis (NASH) patients with type 2 diabetes.Morita Y, Ueno T,
Sasaki N, Tateishi Y, Nagata E, Kage M, Sata M.Hepatogastroenterology. 2005
Sep-Oct;52(65):1338-43.
Study Design: Randomized Controlled Trial
Synopsis: In the present study we administered nateglinide
to nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes who had
failed to respond adequately to diet and exercise therapy, and we compared
the resulting changes in insulin kinetics and improvements in blood glucose
levels, as well as the concomitant changes in hepatic function, diagnostic
liver images and liver histology, with the results from a non-treated
control group. Subjects for this study consisted of 10 patients with NASH.
They all suffered from diabetes and they were all diagnosed with fatty liver
by abdominal ultrasonography (US) and computed tomography (CT). Nonalcoholic
steatohepatitis was diagnosed as the result of liver biopsy. The subjects
were randomly divided into two groups, the nateglinide-treated group and the
non-treated control group. Each group contained five patients. The members
of the nateglinide-treated group were administered nateglinide every day
(270mg/day) before each meal for a period of 20 weeks. Both groups continued
to receive diet and exercise therapy. Body mass index (BMI), blood
chemistry, plasma glucose and HbAlc, abdominal US and CT were measured
before treatment, and every four weeks thereafter. Liver biopsy was
performed over again at 16 weeks af terinitiating treatment. The results
were compared. Postprandial blood glucose, HbA1c, a 75-g oral glucose
tolerance test, liver function, abdominal US and CT imaging tests and liver
histological findings were all improved after treatment with nateglinide.
Technorati Tags:
Starlix,
Nateglinide,
nonalcoholic-steatohepatitis
|